China's Innovation Moment
From cross-border deals to newcos, faster clinical data is fueling the China innovation story, turning biopharmas from Shanghai to Beijing into global players. Multinational pharma and Western VCs have been the first to capitalize, sourcing innovation from China at record levels.
But testing faster in humans is also a recipe for Western and Asia biotechs to de-risk their own compounds, working with China partners.
This October, BioCentury, BayHelix and Insights Partner McKinsey & Company invite you to visit Shanghai for the 12th China Healthcare Summit. Get a firsthand look at China's biotech ecosystem and build your network with the right biopharmas, investors and CDMOs.